Shanna Fuld

About the Author Shanna Fuld

Shanna J. Fuld is a journalist specializing in finance. Born and raised in Queens, New York, she’s been avoiding dates with finance guys for years – only to find herself becoming one. The former NY1er worked as a videographer, assignment editor and writer for the beloved local news channel before joining the Smarter Analyst team.

Why Facebook (FB) Biggest Bear Sees an 18% Stock Decline

What does it take to have Facebook (FB) remove an account? Do you have to be a sexual harasser?

Could General Electric’s (GE) New Chief Lead a Turnaround for the Stock?

As General Electric (GE) welcomes new chief Larry Culp, Cowen’s analyst Gautam Khanna is weighing in on how he expects the company will fare from …

H.C. Wainwright Reiterates Upbeat View of EyePoint Pharmaceuticals (EYPT) Stock on Back of FDA Approval

EyePoint Pharmaceuticals (EYPT) has a big reason to celebrate this week — the Food and Drug Administration (FDA) approved the vision-improving technology. The fluocinolone …

This Analyst Presses the ‘Buy’ Button on Vascular Biogenics (VBLT) Stock; Here’s Why

It’s one small step forward for Vascular Biogenics (VBLT), one giant leap for the company’s stock rating. H.

This Analyst Cheers for AcelRx (ACRX), the Little Opioid Company that Could

Drug company AcelRx (ACRX) is likely celebrating its first win after getting news from the Food and Drug Administration (FDA) late Friday afternoon …

This Top Analyst Bets on Netflix (NFLX) Stock Ahead of Earnings, Should You?

It’s been a bit of a roller coaster for Netflix (NFLX) backers and even though the video streaming service’s stock price has fallen …

Spooked Investors Send Trevena (TVRN) Stock Spiraling as the Company’s Lead Drug Candidate Faces Major Downfall

The US Food and Drug Administration (FDA) puts the needle in the arm of drug company Trevena (TRVN). The agency’s critical briefing documents …